Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events?
Modern data on comorbidity in coronary artery disease (CAD) are presented in the article, as well as its frequency, dependence on the age, clinical and prognostic significance, and increasing relevance for practical health care. The positions of one of the components of cardiovascular comorbidity –...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2020-09-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/2259 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227578029637632 |
|---|---|
| author | O. L. Barbarash V. V. Kashtalap I. A. Shibanova |
| author_facet | O. L. Barbarash V. V. Kashtalap I. A. Shibanova |
| author_sort | O. L. Barbarash |
| collection | DOAJ |
| description | Modern data on comorbidity in coronary artery disease (CAD) are presented in the article, as well as its frequency, dependence on the age, clinical and prognostic significance, and increasing relevance for practical health care. The positions of one of the components of cardiovascular comorbidity – multifocal atherosclerosis – are presented. The existing approaches to the detection and clinical assessment of multifocal atherosclerosis, as well as to the management of the high risk of ischemic events in such patients, are outlined. The main positions on the prevention of the risk of cardiovascular complications in patients with CAD and atherosclerosis of the peripheral arteries using a combination of the anticoagulant – rivaroxaban and the antiplatelet agent – acetylsalicylic acid, are highlighted on the basis of the results of clinical studies. Promising possibilities of using such a therapeutic approach to the management of comorbid patients in routine clinical practice are presented. |
| format | Article |
| id | doaj-art-608dc734fcc9416e8a8456d9347742b1 |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2020-09-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-608dc734fcc9416e8a8456d9347742b12025-08-23T10:00:32ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532020-09-0116460761310.20996/1819-6446-2020-08-081776Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events?O. L. Barbarash0V. V. Kashtalap1I. A. Shibanova2Research Institute for Complex Issues of Cardiovascular DiseasesResearch Institute for Complex Issues of Cardiovascular DiseasesResearch Institute for Complex Issues of Cardiovascular DiseasesModern data on comorbidity in coronary artery disease (CAD) are presented in the article, as well as its frequency, dependence on the age, clinical and prognostic significance, and increasing relevance for practical health care. The positions of one of the components of cardiovascular comorbidity – multifocal atherosclerosis – are presented. The existing approaches to the detection and clinical assessment of multifocal atherosclerosis, as well as to the management of the high risk of ischemic events in such patients, are outlined. The main positions on the prevention of the risk of cardiovascular complications in patients with CAD and atherosclerosis of the peripheral arteries using a combination of the anticoagulant – rivaroxaban and the antiplatelet agent – acetylsalicylic acid, are highlighted on the basis of the results of clinical studies. Promising possibilities of using such a therapeutic approach to the management of comorbid patients in routine clinical practice are presented.https://www.rpcardio.online/jour/article/view/2259multifocal atherosclerosiscoronary artery diseasecomorbidityprognosisrivaroxaban |
| spellingShingle | O. L. Barbarash V. V. Kashtalap I. A. Shibanova Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? Рациональная фармакотерапия в кардиологии multifocal atherosclerosis coronary artery disease comorbidity prognosis rivaroxaban |
| title | Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? |
| title_full | Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? |
| title_fullStr | Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? |
| title_full_unstemmed | Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? |
| title_short | Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? |
| title_sort | cardiovascular comorbidity patient with coronary artery disease and peripheral artery atherosclerosis how to identify and manage the risks of ischemic events |
| topic | multifocal atherosclerosis coronary artery disease comorbidity prognosis rivaroxaban |
| url | https://www.rpcardio.online/jour/article/view/2259 |
| work_keys_str_mv | AT olbarbarash cardiovascularcomorbiditypatientwithcoronaryarterydiseaseandperipheralarteryatherosclerosishowtoidentifyandmanagetherisksofischemicevents AT vvkashtalap cardiovascularcomorbiditypatientwithcoronaryarterydiseaseandperipheralarteryatherosclerosishowtoidentifyandmanagetherisksofischemicevents AT iashibanova cardiovascularcomorbiditypatientwithcoronaryarterydiseaseandperipheralarteryatherosclerosishowtoidentifyandmanagetherisksofischemicevents |